Endologix, Inc. (NASDAQ: ELGX) announced the presentation of two-year clinical data from the Company's Nellix® EVAS FORWARD IDE trial that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE